✦ LIBER ✦

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

✍ Scribed by Michael P. Manns; Marc Bourlière; Yves Benhamou; Stanislas Pol; Maurizio Bonacini; Christian Trepo; David Wright; Thomas Berg; José L. Calleja; Peter W. White; Jerry O. Stern; Gerhard Steinmann; Chan-Loi Yong; George Kukolj; Joe Scherer; Wulf O. Boecher

Book ID: 116652289
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 767 KB
Volume: 54
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2010.08.040

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

954 BI 201335, A POTENT HCV NS3 PROTEASE

954 BI 201335, A POTENT HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE AND -EXPERIENCED CHRONIC HCV GENOTYPE-1 INFECTION: GENOTYPIC AND PHENOTYPIC ANALYSIS OF THE NS3 PROTEASE DOMAIN

✍ G. Kukolj; Y. Benhamou; M.P. Manns; M. Bourlière; S. Pol; M. Schuchmann; M. Cart 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Cross-species absorption, metabolism, di

Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor

✍ Duan, Jianmin; Yong, Chan-Loi; Garneau, Michel; Amad, Ma’an; Bolger, Gordon; De 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 771 KB

Efficacy of the Protease Inhibitor BI 20

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

✍ Stefan Zeuzem; Tarik Asselah; Peter Angus; Jean–Pierre Zarski; Dominique Larrey; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 915 KB

Characterization of vaniprevir, a hepati

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

✍ Lawitz, Eric; Sulkowski, Mark; Jacobson, Ira; Kraft, Walter K.; Maliakkal, Bened 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 367 KB

Danoprevir, an HCV NS3/4A protease inhib

Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C

✍ Moucari, R.; Forestier, N.; Larrey, D.; Guyader, D.; Couzigou, P.; Benhamou, Y.; 📂 Article 📅 2010 🏛 BMJ Publishing Group 🌐 English ⚖ 234 KB

Exam 2: Efficacy of the Protease Inhibit

Exam 2: Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 78 KB